Previous 10 | Next 10 |
Verrica’s product YCANTH™ is the first and only FDA-approved treatment for molluscum, a highly contagious viral skin infection affecting approximately 6 million people annually in the United States, primarily children YCANTH™ is expected to be available for commerci...
Presentation highlights the antitumor response of VP-315 for the non-surgical treatment of Basal Cell Carcinoma (BCC) as determined by clinical and histological lesion clearance There are approximately 3-4 million diagnoses of basal cell carcinomas in the U.S. each year, with a high unm...
2023-08-08 08:01:09 ET Verrica Pharmaceuticals press release ( NASDAQ: VRCA ): Q2 GAAP EPS of -$0.24 misses by $0.02 . Revenue of $0.18M (-10.0% Y/Y) beats by $0.11M . As of June 30, 2023, Verrica had aggregate cash and cash equivalents of $55.1 million. ...
– In July, FDA approved YCANTH™ for the treatment of molluscum, a highly contagious viral skin infection affecting approximately 6 million people annually in the United States, primarily children – – YCANTH™ launch expected by September 2023 –...
WEST CHESTER, Pa., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the acceptance of...
– Verrica received $50M upon the close of the transaction; $75M of additional capital available in tranches based on the achievement of certain revenue milestones – – Proceeds from the transaction to support the commercialization of YCANTH™, which was approved ...
2023-07-25 08:19:12 ET Electra Battery Materials ( NASDAQ: ELBM ) +66% . Bullfrog AI Holdings ( BFRG ) +33% a nnounces Issuance of U.S. Patent Protecting Novel Prodrugs of Mebendazole and Their Use in Treating Cancer. Enzo Biochem ( ENZ ) +18% ...
2023-07-24 15:16:36 ET Shares of Verrica Pharmaceuticals (NASDAQ: VRCA) were down more than 30% as of 2:45 p.m. on Monday. The company, which specializes in dermatology therapeutics, said it was entering into an agreement for as much as $125 million in financing to fund operations. ...
2023-07-24 10:09:58 ET Gainers: Armata Pharmaceuticals ( ARMP ) +19% . Janux Therapeutics ( JANX ) +11% . Amylyx Pharmaceuticals ( AMLX ) +8% . Coherus BioSciences ( CHRS ) +7% . Nuwellis ( NUWE ) +7% . Losers: Kodiak...
2023-07-24 08:34:47 ET Kodiak Sciences ( KOD ) -53% announces topline results from its phase 3 Studies of tarcocimab tedromer in Neovascular age-related macular degeneration and diabetic macular edema. Contango Ore ( CTGO ) -25% . 22nd Century Group ( XXII ...
News, Short Squeeze, Breakout and More Instantly...
Verrica Pharmaceuticals Inc. Company Name:
VRCA Stock Symbol:
NASDAQ Market:
Verrica Pharmaceuticals Inc. Website:
- Dormer Labs has discontinued the sale of all cantharidin-containing products into the United States - YCANTH is the only commercially available, FDA approved therapy for molluscum contagiosum and is clinically proven to be safe and effective WEST CHESTER, Pa., July 01, 202...
WEST CHESTER, Pa., May 30, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Pr...
Global pivotal Phase 3 clinical trial would be conducted jointly by Verrica and Torii Pharmaceutical; trial expected to begin in the 1 st half of 2025 Amendment should benefit both parties from a cost and time to market standpoint; funding structure is expected to have a min...